Question n° 5: Quoi de neuf dans les indications thérapeutiques de la TE?
- Author
- KILADJIAN, Jean-Jacques1
[1] Service d'hématologie, Hôpital Avicenne, Université Paris-XIII, Bobigny, France - Issue title
- Forum polémique. Diagnostic, pronostic et traitement des syndromes myéloprolifératifs BCR/ABL négatifs
- Author (monograph)
- BRIERE, Jean (Editor)1
[1] Hôpital Beaujon, Clichy, France - Source
Hématologie (Montrouge). 2009, Vol 15, pp 22-26, 5 p ; NS2 ; ref : 11 ref
- ISSN
- 1264-7527
- Scientific domain
- Hematology
- Publisher
- John Libbey Eurotext, Montrouge
- Publication country
- France
- Document type
- Article
- Language
- French
- Keyword (fr)
- Anagrélide Homme Hématologie Indication Inhibiteur thromboagrégation Traitement Thrombocytémie essentielle Cancer Dérivé de la quinazoline Hémopathie maligne Syndrome myéloprolifératif
- Keyword (en)
- Anagrelide Human Hematology Indication Antiplatelet agent Treatment Essential thrombocythemia Cancer Quinazoline derivatives Malignant hemopathy Myeloproliferative syndrome
- Keyword (es)
- Anagrelida Hombre Hematología Indicación Inhibidor tromboagregación Tratamiento Trombocitemia esencial Cáncer Hemopatía maligna Mieloproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02G Blood. Blood coagulation. Reticuloendothelial system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 21934371
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:9:\"\u0000*\u0000jtitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:9:\"\u0000*\u0000stitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"15\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"22\";s:8:\"\u0000*\u0000epage\";s:2:\"26\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1264-7527\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KILADJIAN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Jean-Jacques\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:3:\"NS2\";s:9:\"\u0000*\u0000btitle\";s:106:\"Forum pol\u00e9mique. Diagnostic, pronostic et traitement des syndromes my\u00e9loprolif\u00e9ratifs BCR\/ABL n\u00e9gatifs\";s:8:\"\u0000*\u0000title\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:8:\"\u0000*\u0000place\";s:9:\"Montrouge\";s:6:\"\u0000*\u0000pub\";s:20:\"John Libbey Eurotext\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:9:\"\u0000*\u0000jtitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:9:\"\u0000*\u0000stitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"15\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"22\";s:8:\"\u0000*\u0000epage\";s:2:\"26\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1264-7527\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KILADJIAN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Jean-Jacques\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:3:\"NS2\";s:9:\"\u0000*\u0000btitle\";s:106:\"Forum pol\u00e9mique. Diagnostic, pronostic et traitement des syndromes my\u00e9loprolif\u00e9ratifs BCR\/ABL n\u00e9gatifs\";s:8:\"\u0000*\u0000title\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:8:\"\u0000*\u0000place\";s:9:\"Montrouge\";s:6:\"\u0000*\u0000pub\";s:20:\"John Libbey Eurotext\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:9:\"\u0000*\u0000jtitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:9:\"\u0000*\u0000stitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"15\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"22\";s:8:\"\u0000*\u0000epage\";s:2:\"26\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1264-7527\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KILADJIAN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Jean-Jacques\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:3:\"NS2\";s:9:\"\u0000*\u0000btitle\";s:106:\"Forum pol\u00e9mique. Diagnostic, pronostic et traitement des syndromes my\u00e9loprolif\u00e9ratifs BCR\/ABL n\u00e9gatifs\";s:8:\"\u0000*\u0000title\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:8:\"\u0000*\u0000place\";s:9:\"Montrouge\";s:6:\"\u0000*\u0000pub\";s:20:\"John Libbey Eurotext\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:9:\"\u0000*\u0000jtitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:9:\"\u0000*\u0000stitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"15\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"22\";s:8:\"\u0000*\u0000epage\";s:2:\"26\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1264-7527\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KILADJIAN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Jean-Jacques\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:3:\"NS2\";s:9:\"\u0000*\u0000btitle\";s:106:\"Forum pol\u00e9mique. Diagnostic, pronostic et traitement des syndromes my\u00e9loprolif\u00e9ratifs BCR\/ABL n\u00e9gatifs\";s:8:\"\u0000*\u0000title\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:8:\"\u0000*\u0000place\";s:9:\"Montrouge\";s:6:\"\u0000*\u0000pub\";s:20:\"John Libbey Eurotext\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:9:\"\u0000*\u0000jtitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:9:\"\u0000*\u0000stitle\";s:24:\"H\u00e9matologie (Montrouge)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"15\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"22\";s:8:\"\u0000*\u0000epage\";s:2:\"26\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1264-7527\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KILADJIAN\";s:10:\"\u0000*\u0000aufirst\";s:12:\"Jean-Jacques\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:3:\"NS2\";s:9:\"\u0000*\u0000btitle\";s:106:\"Forum pol\u00e9mique. Diagnostic, pronostic et traitement des syndromes my\u00e9loprolif\u00e9ratifs BCR\/ABL n\u00e9gatifs\";s:8:\"\u0000*\u0000title\";s:75:\"Question n\u00b0 5: Quoi de neuf dans les indications th\u00e9rapeutiques de la TE?\";s:8:\"\u0000*\u0000place\";s:9:\"Montrouge\";s:6:\"\u0000*\u0000pub\";s:20:\"John Libbey Eurotext\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
